TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in P-wave terminal force (Ptf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Family coping
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Brief Arthritis Stiffness Scale (BASS) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cortical oxy-haemoglobin (HbO2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement or Resolution of Arytenoid Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication rate of perineal wound
Endpoint domain: Adverse events/effects
Primary endpoint: Change in skin effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Titers of anti-nucleoprotein (NP) or anti-hemagglutinin (HA) antibody (IgG and IgM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Titer of neutralization antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Flexion and extension degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full Mayo Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukine - 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sputum colour evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peri- and post-operative parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: concentration of analytes (lipids, proteins/amino acids)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of detectable analytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PV loop-based hemodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Adverse Events During Each Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: Days of newborn morphine treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fasting low-density lipoprotein cholesterol (LDL-C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MogPWV (m/s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PP (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absolute change in Total Clinical Score (TCS) of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Reporting One or More Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Advance Care Planning Bills
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Retention and drop out rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of EORTC QLQ-C30 at 1.5 month
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of EORTC QLQ-C30 at 3 month
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dose-normalized AUC of Mycophenolic Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faecal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faecal microbiota activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stool bacterial populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Microvascular blood volume in response to feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HIV-RNA plasma viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Prescription for an FDA-approved Smoking Cessation Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: weeks of abstinence from the primary drug of dependence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change in UPDRS III Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Steps Taken in 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the UroMark assay to detect bladder cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Asthma First Aid Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Standardized digital imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6-minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival following infusion of RP-L201
Endpoint domain: Mortality/survival
Primary endpoint: brachial artery flow mediated vasodilation (FMV%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Free time to disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Boston Carpal Tunnel Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnostic yield of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure difference with positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in symptom relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Visual analog scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: target gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of in vivo persistence of transferred T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The nature, frequency and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: The Laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Skeletal Related Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ovarian reserve estimated by laboratory test (Blood sample for AMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Ovarian reserve estimated by ultrasound evaluation (AFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Objective Response (OR) to Kadcyla
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Binge drinking frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Drinking frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Drinking quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Drinking problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in the 6 Minute Walk Test (6MWT) Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Social Communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Tolerance of a new fast MR method in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Cytogenetic Response (MCyR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall Hematological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in the Mean Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in self-efficacy score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: novel protein biomarkers in tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinically Significant Hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Initial change in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Therapeutic effect after electroconvulsive treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Seizure Free Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes From Baseline Smoking Behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fasting thromboxane B2 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: after breakfast thromboxane B2 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Disability of Arm, Shoulder and Hand (DASH) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adipocytokines levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: undetectable blood viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: detectable VL in semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients interacting with tablet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Specific Immune Responses to Vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Nutritional Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Food Ingestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Level of Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under curve (AUC) 0~∞
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse oximetric saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calculated oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of the potential evoked
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Binary Restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Severity of Post-Operative Sore Throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Empowerment to self-care
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Positive culture
Endpoint domain: Adverse events/effects
Primary endpoint: Prediction of Sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AUC of AZD9291
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fungus detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulative incidence rate of all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence rate of non-fatal myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative incidence rate of all unplanned revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post-procedure chest discomfort scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes management and control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients Receiving Appropriate Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Therapeutic Cure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD symptoms (ASRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in best corrected visual acuity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability Measured by Percent of Participants Completing the rTMS Course
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Decrease in Cue Induced Nicotine Craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Newly Diagnosed Atrial Fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of falimarev
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: VAS groups comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear and Behavior Intent Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State and Trait Anxiety Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Efficacy - Sufficiency Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in median headache score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in AUC 0-4h post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Modified-Unified Parkinson's Disease Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of Hamilton Rating Scale for Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Taiwanese Depression Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of rescue general anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with changes in safety cardiac parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with changes in clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with clinically significant abnormal vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enrollment and retention of participants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients achieving remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung cancer incidence rate
Endpoint domain: Mortality/survival
Primary endpoint: HIV-1 load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression of liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least 1-point Improvement on the Allergan Cheek Smoothness Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experience One or More Treatment Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of paliperidone in plasma and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: (+) and (-) paliperidone ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute oral bioavailability of paliperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal venous pressure (RVP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Panic Disorder diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Virological rebound
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Activin A levels in BAL fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in cytokine levels in BAL fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in surfactant protein C levels in BAL fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of lucerastat after single ascending doses of lucerastat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of lucerastat after two daily doses of lucerastat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Grade 4 Hemorrhage or Grade 5 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CNV activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture healing time at 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abnormal cognitive functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: abnormal pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: reduced health related quality-of-life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Who Were Responders or Low-Responders of Antiplatelet Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects With ≥1 Treatment-emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: ocular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of the CoolSculpting and the CoolCurve+ Applicator
Endpoint domain: Adverse events/effects
Primary endpoint: Post-traumatic Stress Disorder severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of idelalisib and lenalidomide
Endpoint domain: Adverse events/effects
Primary endpoint: Minutes and days per week of walking and strength training exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of peritoneal metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients free from peritoneal metastasis after one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pocket hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Orthodontic Anterior Alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of bone in millimeters after extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Freedom from clinically driven target lesion revascularization
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of reported medication errors (missed doses)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduced Cholesterol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduced Lipid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Adverse Events (AEs) and/or Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of MRE and c-T1 to assess disease progress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bactericidal effect
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of the GBS conjugate vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Heart failure symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fear of Falling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MRI image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative duration of abnormal SSEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Drug-related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Response - No Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes